ArticleInvestigative ophthalmology & visual science2026
Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to elucidate the effects and mechanisms of liraglutide in repairing diabetic corneal epithelial injury, explore its therapeutic advantages, and provide experimental evidence for clinical application. Methods: GLP-1R expression in mouse corneal epithelium was detected by Western blotting, qPCR, and immunofluorescence. Streptozotocin-induced diabetic mice and 30 mM high-glucose (HC) cell models were established. Epithelial wound healing, viability, proliferation, migration, and apoptosis were evaluated by fluorescein staining, TUNEL, CCK-8, EdU, and scratch assay. Bioinformatics was used to screen differentially expressed genes. Reactive oxygen species (ROS), redox indicators, and key proteins in Keap1-Nrf2-ARE, PI3K/Akt, and MAPK pathways were measured. PI3K inhibitors were applied to verify the pathway function, and macrophage polarization and recruitment were further assessed. Results: GLP-1R was mainly located in the deep basal cells of corneal epithelium. Liraglutide improved cell viability, promoted proliferation and migration, and inhibited apoptosis. It restored redox balance and alleviated oxidative stress via activating Nrf2/HO-1/NQO-1 pathway, and enhanced cell functions through PI3K/Akt pathway; these effects were abolished by PI3K inhibition. Moreover, liraglutide reduced aberrant macrophage infiltration, promoted anti-inflammatory macrophage polarization, and decreased pro-inflammatory factors, which was associated with MAPK pathway downregulation. Conclusions: Liraglutide exerts multi-mechanism protective effects on diabetic corneal epithelium. It regulates Nrf2 and PI3K/Akt pathways to attenuate oxidative stress and improve cell functions, and modulates macrophage polarization and recruitment via MAPK pathway to relieve inflammation, thereby promoting corneal epithelial injury repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.